[go: up one dir, main page]

RU94036770A - Protease inhibitor domain, dna, cell, method of domain preparing, pharmaceutical composition, domain use - Google Patents

Protease inhibitor domain, dna, cell, method of domain preparing, pharmaceutical composition, domain use

Info

Publication number
RU94036770A
RU94036770A RU94036770/13A RU94036770A RU94036770A RU 94036770 A RU94036770 A RU 94036770A RU 94036770/13 A RU94036770/13 A RU 94036770/13A RU 94036770 A RU94036770 A RU 94036770A RU 94036770 A RU94036770 A RU 94036770A
Authority
RU
Russia
Prior art keywords
cys
amino acid
glu
phe
domain
Prior art date
Application number
RU94036770/13A
Other languages
Russian (ru)
Inventor
Норрис Фанни
Dk]
Норрис Келль
Эрик Бьерн Серен
Кристиан Петерсен Ларс
Вильстед Ольсен Оле
Original Assignee
Ново Нордиск А/С (DK)
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С (DK), Ново Нордиск А/С filed Critical Ново Нордиск А/С (DK)
Priority claimed from RU94036773/13A external-priority patent/RU94036773A/en
Publication of RU94036770A publication Critical patent/RU94036770A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FIELD: biochemistry, peptide chemistry. SUBSTANCE: protease inhibitor of Kunitz type, in part, inhibitor of tissue factor metabolism has the followingaminoacidsequence:X-Asp-Phe-Cys-Phe-Leu--Glu-Glu-Asp--X-Gly-X-Cys-X, X, X, X, X, X-Tyr-Phe-Tyr-Asn-Asn-Glu-Thr- -Lys-Gln-Thr-Lys-Gln-Cys-Glu-Arg-Phe-X-Tyr-Gly-Gly-Cys-X, X, X- -Met-Asn-Phe-X-Thr-Leu-Glu-Gly-Cys-Lys-Asn-Ile-Cys-X-Asp- -X(sequence ID N 1) where Xis H or 1-5 natural amino acid residues for exception Cys; every of X-Xmeans independently natural amino acid residue, and Xmeans OH or 1-5 natural amino acid residues for exception Cys; at condition that at least one of amino acid residues X-Xdistincts of the corresponding amino acid residue of native sequence. EFFECT: enhanced effectiveness of inhibitor.

Claims (1)

Вариант домена 11 ингибитора протеазы человека типа Кунитца, а именно ингибитора метаболизма тканевого фактора (TFPI), где указанный вариант содержит следующую аминокислотную последовательность: Х1, Аsр, Phe, Суs, Рhе, Lеu, Glu, Glu, Аsр, Х2, Gly, Х3, Cys, Х4, Х5, Х6, Х7, Х8, Х9, Туr, Рhe, Туr, Asn, Аsn, Glu, Тhr, Lys, Gln, Тhr, Lys, Gln, Cys, Glu, Аrg, Рhе, X10, Туr, Gly, Gly, Суs, X11, X12, Х13, Met, Аsn, Рhе, Х14, Тhr, Lеu, Glu, Gly, Cys, Lys, Аsn, Ile, Cys, Gl, Аsp, Х15 (SEQ 1D N 1), где Х1 -H или 1 - 5 природных аминокислотных остатков, за исключением Cys; каждый из Х2 - Х14 - независимо природный аминокислотный остаток, а Х15 - ОН или 1 - 5 природных аминокислотных остатков, за исключением Суs; при условии, что по крайней мере один из аминокислотных остатков Х1 - X15 отличается от соответствующего аминокислотного остатка нативной последовательности.A variant of domain 11 of a Kunitz-type human protease inhibitor, namely a tissue factor metabolism inhibitor (TFPI), wherein said variant contains the following amino acid sequence: X 1 , Asp, Phe, Cus, Phe, Leu, Glu, Glu, Asp, X 2 , Gly , X 3 , Cys, X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , Tur, Phe, Tur, Asn, Asn, Glu, Thr, Lys, Gln, Thr, Lys, Gln, Cys, Glu, Arg, Phe, X 10 , Tur, Gly, Gly, Cys, X 11 , X 12 , X 13 , Met, Asn, Phe, X 14 , Thr, Leu, Glu, Gly, Cys, Lys, Asn, Ile , Cys, Gl, Asp, X 15 (SEQ 1D N 1), where X 1 -H or 1 to 5 natural amino acid residues, with the exception of Cys; each of X 2 - X 14 is independently a natural amino acid residue, and X 15 is OH or 1 to 5 natural amino acid residues, with the exception of Sus; provided that at least one of the amino acid residues X 1 to X 15 is different from the corresponding amino acid residue of the native sequence.
RU94036770/13A 1992-01-07 1993-01-07 Protease inhibitor domain, dna, cell, method of domain preparing, pharmaceutical composition, domain use RU94036770A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATDK92/00001 1992-01-07
RU94036773/13A RU94036773A (en) 1992-01-07 1993-01-07 Domain i of protease inhibitor, dna, vector, cell, method of protease inhibitor preparing, pharmaceutical composition, the use of domain i

Publications (1)

Publication Number Publication Date
RU94036770A true RU94036770A (en) 1996-09-27

Family

ID=48449360

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94036770/13A RU94036770A (en) 1992-01-07 1993-01-07 Protease inhibitor domain, dna, cell, method of domain preparing, pharmaceutical composition, domain use

Country Status (1)

Country Link
RU (1) RU94036770A (en)

Similar Documents

Publication Publication Date Title
RU94036773A (en) Domain i of protease inhibitor, dna, vector, cell, method of protease inhibitor preparing, pharmaceutical composition, the use of domain i
KR940703854A (en) A HUMAN KUNITZ-TYPE PROTEASE INHIBITOR VARIANT
DE10075019I2 (en) New proteins with TNF inhibitory activity and their production.
DK165988B (en) MODIFIED EGLINES B AND C, THEIR USE AS PROTEASE INHIBITORS, PROCEDURES FOR PREPARING IT, AND PHARMACEUTICAL PREPARATIONS CONTAINING THE MODIFIED EGLINES B AND C
RU94036776A (en) Domain of protease inhibitor, dna, vector, cell, method of protease inhibitor preparing, pharmaceutical composition, the use of protease inhibitor domain
RU94045952A (en) Domain of protease inhibitor, dna, vector, cell, method of preparing protease inhibitor, pharmaceutical composition, use of domain
KR940703860A (en) Novel human Kunizin protease inhibitors and variants thereof (A NOVEL HUMAN KUNITZ-TYPE PROTEASE INHIBITOR AND VARIANTS THEREOF)
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
ATE84547T1 (en) PURIFIED INTERLEUKIN-1.
US6096864A (en) Peptides for use in wound treatment
Joubert et al. The complete amino acid sequence of trypsin inhibitor DE-3 from Erythrina latissima seeds.
Ramage et al. Solid phase peptide synthesis of ubiquitin
RU94036770A (en) Protease inhibitor domain, dna, cell, method of domain preparing, pharmaceutical composition, domain use
RU99116976A (en) MYELOPEPTIDES AND THEIR THERAPEUTIC USE
NO20016341L (en) Inhibitors for the integrin <alfa> v <beta> 6
KR890014735A (en) Modified protein
EP0858808A2 (en) Peptides for use in wound treatment
KR950703357A (en) INHIBTION OF RETROVIRUS INFECTION
WEITZEL et al. Structure and Activity of Insulin, XV. Further Evidence for the Importance of Arginine Residue B 22 in the Activity of Insulin. Semisyntheses of Despentapeptide-(B 26-30)-Insulins Varied in B 22 Using Desnonapeptide-(B 22-30)-Insulin and Tetrapeptides
KR940703855A (en) A HUMAN KUNITZ-TYPE PROTEASE INHIBITOR VARIANT
KNORR et al. [B17-D-Leucine] Insulin and [B17-Norleucine] Insulin: synthesis and biological properties
RU94036002A (en) Protease inhibitor, dna, vector, cell, method of inhibitor preparing, pharmaceutical composition
Bodenmuller Isolation and structural analysis of a new neuropeptide, the head activator
AU628653B2 (en) Novel cns-active hexapeptides with an antiamnesic effect
TH26711A (en) "Homone secretion of growth factor"